Want to see HK:1477 full AI Analyst Report?
Total Valuation
Ocumension Therapeutics has a market cap or net worth of HK$4.14B. The enterprise value is HK$3.33B.
Market CapHK$4.14B
Enterprise ValueHK$3.33B
Share Statistics
Ocumension Therapeutics has 836,331,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding836,331,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ocumension Therapeutics’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -4.11%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-4.11%
Return on Capital Employed (ROCE)-0.04
Revenue Per Employee1.32M
Profits Per Employee-260.64K
Employee Count608
Asset Turnover0.20
Inventory Turnover6.93
Valuation Ratios
The current PE Ratio of Ocumension Therapeutics is ―. Ocumension Therapeutics’s PEG ratio is 0.68.
PE Ratio―
PS Ratio6.54
PB Ratio1.43
Price to FCF-14.66
Price to Operating Cash Flow-278.70
PEG Ratio0.68
Income Statement
In the last 12 months, Ocumension Therapeutics had revenue of 804.35M and earned -158.82M in profits. Earnings per share was -0.20.
Revenue804.35M
Gross Profit360.92M
Operating Income-160.20M
Pretax Income-158.47M
Net Income-158.82M
EBITDA-16.47M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -12.83M and capital expenditures -261.56M, giving a free cash flow of -274.38M billion.
Operating Cash Flow-12.83M
Free Cash Flow-274.38M
Free Cash Flow per Share-0.33
Dividends & Yields
Ocumension Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change-36.82%
50-Day Moving Average5.25
200-Day Moving Average6.35
Relative Strength Index (RSI)45.49
Average Volume (3m)339.18K
Important Dates
Ocumension Therapeutics upcoming earnings date is Mar 19, 2027, TBA (Confirmed).
Last Earnings DateAug 28, 2026
Next Earnings DateMar 19, 2027
Ex-Dividend Date―
Financial Position
Ocumension Therapeutics as a current ratio of 3.70, with Debt / Equity ratio of 7.96%
Current Ratio3.70
Quick Ratio3.46
Debt to Market Cap0.03
Net Debt to EBITDA13.06
Interest Coverage Ratio-67.26
Taxes
In the past 12 months, Ocumension Therapeutics has paid 350.00K in taxes.
Income Tax350.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Ocumension Therapeutics EV to EBITDA ratio is -306.24, with an EV/FCF ratio of -14.06.
EV to Sales6.27
EV to EBITDA-306.24
EV to Free Cash Flow-14.06
EV to Operating Cash Flow-47.90
Balance Sheet
Ocumension Therapeutics has HK$268.31M in cash and marketable securities with HK$288.55M in debt, giving a net cash position of -HK$20.23M billion.
Cash & Marketable SecuritiesHK$268.31M
Total DebtHK$288.55M
Net Cash-HK$20.23M
Net Cash Per Share-HK$0.02
Tangible Book Value Per ShareHK$1.37
Margins
Gross margin is 47.19%, with operating margin of -19.92%, and net profit margin of -19.75%.
Gross Margin47.19%
Operating Margin-19.92%
Pretax Margin-19.70%
Net Profit Margin-19.75%
EBITDA Margin-2.05%
EBIT Margin-19.92%
Analyst Forecast
The average price target for Ocumension Therapeutics is HK$7.92, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$7.92
Price Target Upside4.90% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast77.55%
EPS Growth Forecast50.34%